Clinical Trials Logo
  1. Home
  2. Eczema
  3. NCT06230991

A Pilot Study of Efficacy and Safety of SIM05 in Adults With Atopic Eczema

Atopic Eczema Clinical Trial

Official title:
A Pilot Study of Efficacy and Safety of a Microbiome Immunity Formula (SIM05) in Adults With Atopic Eczema

Clinical Trial Summary

Atopic eczema causes significant disease burdens worldwide. Some studies reported gastrointestinal symptoms in eczema patients which could be related to gut microbiota change. A unique gastrointestinal microflora pattern has also been observed in atopic dermatitis patients when compared with healthy controls. To date, no adult formula is specific for alleviating atopic eczema-related symptoms (especially through change of gut microbiota) for adults. The investigators hypothesize that the gut microbiota of adults with atopic eczema can be modulated to decrease the severity of atopic eczema-related symptoms. A pilot study is proposed to assess the effect and safety of SIM05 on atopic eczema severity and gut microbiome of adults with atopic eczema.

Clinical Trial Description

The major atopic disorders, atopic eczema, allergic rhinitis and asthma, cause significant disease burdens worldwide. Apart from cutaneous symptoms such as dryness and itchiness in eczema patients [4], studies also reported gastrointestinal symptoms which could be related to gut microbiota change. Unique gastrointestinal microflora pattern has also been observed in atopic dermatitis patients when compared with healthy controls: decreased Bifidobacterium and Enterococci, especially Bifidobacterium bifidum and Bifidobacterium longum, and increased Faecalibacterium have been observed. Therefore, gastrointestinal microflora can serve as the disease indicator of atopic eczema. Emerging evidence also suggests that gut microbiota modulation can largely affect host immune functions in adults. To date, no adult formula is specific for alleviating atopic eczema-related symptoms (especially through change of gut microbiota) for adults. SIM05 contains a blend of naturally occurring three food-grade probiotics strains and three prebiotics. The three probiotics belong to food-grade Bifidobacterium and Lactobacillus, which is an important group of probiotic cultures commonly used in food products. Moreover, research showed that Lactobacillus and Bifidobacteria could prevent atopic sensitisation to common food allergens and thus reducing the incidence of atopic eczema. The investigators hypothesize that the gut microbiota of adult with atopic eczema can be modulated to decrease the severity of atopic eczema related symptoms. A pilot study of 30 adults with atopic eczema who will receive SIM05 for 16 weeks is proposed to assess the effect and safety of SIM05 on atopic eczema severity and gut microbiome. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06230991
Study type Interventional
Source Chinese University of Hong Kong
Contact Yee Ting Fung, BSc
Phone 26373207
Email yeetingfung@cuhk.edu.hk
Status Recruiting
Phase N/A
Start date October 10, 2023
Completion date February 28, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02381028 - Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children N/A
Completed NCT00484003 - A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis Phase 4
Completed NCT05454722 - A Study to Evaluate Adex Gel in the Treatment of Atopic Eczema. N/A
Completed NCT01854580 - Evaluation of an Integrated Care Project
Completed NCT00555178 - Regulatory T Cells (Tregs) in Polymorphic Light Eruption N/A
Completed NCT00559546 - Montelukast as a Controller of Atopic Syndrome Phase 4
Completed NCT00224432 - Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis N/A
Active, not recruiting NCT03143504 - A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study
Active, not recruiting NCT03409367 - A Community-based Assessment of Skin Care, Allergies, and Eczema N/A
Not yet recruiting NCT06453512 - A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema N/A
Completed NCT00826592 - Comparison of Video-Based Versus Written Patient Education on Atopic Dermatitis N/A
Completed NCT00576238 - Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser Phase 3
Active, not recruiting NCT05590585 - Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Phase 4
Completed NCT01119313 - Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema Phase 2
Completed NCT00676884 - A Phase 2a Study to Investigate the Effects of Repeated Administration of AeroDerm in Subjects With Atopic Eczema Phase 2
Recruiting NCT03270566 - Softened Water for Eczema Prevention Pilot Trial N/A
Completed NCT02300701 - Role of Anti-IgE in Severe Childhood Eczema Phase 4
Completed NCT04114097 - The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover Phase 4
Completed NCT02915146 - Narrowband Ultraviolet B Versus Narrowband Ultraviolet B Plus Ultraviolet A1 for Atopic Eczema N/A
Recruiting NCT00771121 - Effect of Moisturizing Creams on Skin Barrier Function Phase 4